Laine A, Nagelli S, Farrington C, Butt U, Cvrljevic A, Vainonen J, et al. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. Cancer Res. 2021;81:4319-4331 pubmed publisher

Ventelä S, Sittig E, Mannermaa L, Mäkelä J, Kulmala J, Löyttyniemi E, et al. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance. Oncotarget. 2015;6:144-58 pubmed

Lin Y, Hu Q, Mazzagatti A, Valle Incl xe1 n J, Maurais E, Dahiya R, et al. Mitotic clustering of pulverized chromosomes from micronuclei. Nature. 2023;618:1041-1048 pubmed publisher

Routila J, Suvila K, Grenman R, Leivo I, Westermarck J, Ventelä S. Cancer cell line microarray as a novel screening method for identification of radioresistance biomarkers in head and neck squamous cell carcinoma. BMC Cancer. 2021;21:868 pubmed publisher

Umesalma S, Kaemmer C, Kohlmeyer J, Letney B, Schab A, Reilly J, et al. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. J Clin Invest. 2019;130:1641-1653 pubmed publisher

Gomes L, Menck C, Cuervo A. Chaperone-mediated autophagy prevents cellular transformation by regulating MYC proteasomal degradation. Autophagy. 2017;13:928-940 pubmed publisher

Mannava S, Omilian A, Wawrzyniak J, Fink E, Zhuang D, Miecznikowski J, et al. PP2A-B56? controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene. 2012;31:1484-92 pubmed publisher

Choi Y, Park J, Park M, Oh K, Lee M, Lim J, et al. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett. 2011;585:755-60 pubmed publisher